The rationale for targeting the LOX family in cancer

Nat Rev Cancer. 2012 Jul 19;12(8):540-52. doi: 10.1038/nrc3319.


The therapeutic targeting of extracellular proteins is becoming hugely attractive in light of evidence implicating the tumour microenvironment as pivotal in all aspects of tumour initiation and progression. Members of the lysyl oxidase (LOX) family of proteins are secreted by tumours and are the subject of much effort to understand their roles in cancer. In this Review we discuss the roles of members of this family in the remodelling of the tumour microenvironment and their paradoxical roles in tumorigenesis and metastasis. We also discuss how targeting this family of proteins might lead to a new avenue of cancer therapeutics.

Trial registration: NCT01323933.

Publication types

  • Review

MeSH terms

  • Animals
  • Cell Transformation, Neoplastic / metabolism*
  • Cell Transformation, Neoplastic / pathology
  • Humans
  • Molecular Targeted Therapy
  • Neoplasm Metastasis
  • Neoplasms / enzymology*
  • Neoplasms / pathology
  • Neoplasms / therapy*
  • Protein-Lysine 6-Oxidase / metabolism*
  • Tumor Microenvironment


  • Protein-Lysine 6-Oxidase

Associated data